EUCTR2006-001786-42-GR进行中（未招募）不适用
An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis - CASSIOPEA
sanofi-Aventis recherche & developpement0 个研究点目标入组 3,200 人开始时间: 2006年10月2日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Confirmed acute symptomatic PE with or without confirmed acute symptomatic DVT of the lower limbs.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Legal lower age limitations (country specific)
- •2. Women with childbearing potential without proper contraceptive measures
- •3. Written informed consent not obtained
- •4. Other indication than current episode of PE for anticoagulation
- •5. Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE
- •6. Treatment with a therapeutic dose of any LMWH or UFH for more than 36 hours immediately preceding randomization
- •7. Life expectancy < 6 months
- •8. Participation, within the prior 30 days, in another pharmacotherapeutic study with non-registered investigational product
- •9. Pregnancy
- •10. Threatened abortion
- •11. Active major bleeding
- •12. Hemorrhagic tendencies or blood dyscrasias
- •13. Recent or contemplated surgery of central nervous system, eye, traumatic surgery resulting in large open surfaces
- •14. Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding
- •15. Malignant hypertension
- •16. Unsupervised patients with senility, alcoholism, or psychosis, or other lack of patient cooperation
- •17. Known hypersensitivity to warfarin or to any other component of this product
- •18. Patients with hypersensitivity to enoxaparin sodium, heparin, or pork products
- •19. Any other contraindication listed in the labeling of warfarin, or enoxaparin, not listed above
- •20. Breast-feeding
- •21. Creatinine clearance < 10mL/min or end-stage renal failure (i.e. need for renal replacement therapy such as renal transplantation, hemodialysis or peritoneal dialysis).
- •22. Hypersensitivity to idraparinux or SSR126517E
- •23. Known allergy to avidin or egg proteins
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.Peripheral artery diseaseMedDRA version: 20.0Level: LLTClassification code 10053375Term: Peripheral revascularizationSystem Organ Class: 100000004865EUCTR2014-005569-58-DEBayer AG6,500
未知
不适用
An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis - CASSIOPEA-I26I26PER-072-08sanofi-aventis Recherche & Development,
进行中（未招募）
不适用
An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis - CASSIOPEAPatients with confirmed acute symptomatic pulmonary embolism with or without confirmed acute symptomatic deep vein thrombosis of the lower limbs.MedDRA version: 8.1Level: PTClassification code 10051055EUCTR2006-001786-42-NLsanofi-synthelabo recherche3,200
进行中（未招募）
不适用
An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis - CASSIOPEAPatients with confirmed acute symptomatic pulmonary embolism with or without confirmed acute symptomatic deep vein thrombosis of the lower limbs.MedDRA version: 8.1Level: PTClassification code 10037377EUCTR2006-001786-42-SEsanofi-aventis recherche et développement3,200
进行中（未招募）
1 期
Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.Peripheral artery diseaseMedDRA version: 20.0Level: LLTClassification code 10053375Term: Peripheral revascularizationSystem Organ Class: 100000004865EUCTR2014-005569-58-PTBayer AG6,564